Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06958432 | Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) | recruiting | Phase 2 / Phase 3 | 430 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 |
| clinicaltrials |
| NCT07271355 | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial | recruiting | Phase 3 | 129 | City of Hope Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05752136 | Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | recruiting | Phase 3 | 108 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | recruiting | Phase 3 | 408 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07132463 | Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study | recruiting | Phase 3 | 196 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease(STELLAR-316) | recruiting | Phase 3 | 600 | ExelixisINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07676162 | A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer | recruiting | Phase 3 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06501482 | Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI(IRIMAD) | recruiting | Phase 3 | 254 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | recruiting | Phase 3 | 1,020 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer(HARMONi-GI3) | recruiting | Phase 3 | 600 | Summit TherapeuticsINDUSTRY | 14 | Sep 8, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT04749108 | Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma(GRECCAR14) | recruiting | Phase 2 / Phase 3 | 1,075 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT07669519 | Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy(NuvastaticTM) | recruiting | Phase 3 | 180 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05534087 | Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)(CLAUDIA) | recruiting | Phase 3 | 236 | Seoul National University HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07722494 | IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | recruiting | Phase 3 | 550 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07736495 | Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | recruiting | Phase 2 / Phase 3 | 50 | Ain Shams UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06205485 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer(NEO-RT) | recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT06794086 | SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases(SPARKLE-L) | recruiting | Phase 3 | 24 | Jun HuangOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07669454 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.(NuvastaticTM) | recruiting | Phase 3 | 250 | Natureceuticals Sdn BhdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06642844 | Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL) | recruiting | Phase 3 | 244 | University Hospital, ToursOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06783491 | Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer(FOXHIPECT4) | recruiting | Phase 3 | 1,083 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06123156 | Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer(RECTIL) | recruiting | Phase 3 | 188 | University Hospital, RouenOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06758830 | Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. | recruiting | Phase 2 / Phase 3 | 400 | National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06936774 | Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance(iRECOVER) | recruiting | Phase 3 | 140 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 165 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07528209 | Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558083 | FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients(FOLICOLOR) | recruiting | Phase 3 | 150 | University Hospital, AntwerpOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06850090 | Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial | recruiting | Phase 3 | 210 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07412613 | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | recruiting | Phase 3 | 386 | AkesoINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | recruiting | Phase 2 / Phase 3 | 156 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07537998 | Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. | recruiting | Phase 2 / Phase 3 | 160 | Pei-Rong DingOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07018869 | Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | recruiting | Phase 3 | 1,057 | SWOG Cancer Research NetworkNETWORK | 3 | Mar 31, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06497985 | A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients | recruiting | Phase 3 | 430 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06951503 | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04215731 | Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer(FOBEAR) | recruiting | Phase 3 | 582 | Yanhong DengOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials